Karateev A E, Pogozheva E Yu, Filatova E A, Amirjanova V N, Lila A M, Antipova O V, Babaeva A R, Volkorezova A V, Davydova A F, Davtyan V G, Zonova E V, Ivanova O N, Kalinina N N, Kiseleva N I, Knyazeva L A, Kulikov A I, Nesmeyanova O B, Mazurov V I, Masneva L V, Menshikova L V, Obuhova I V, Otteva E N, Salnikova T S, Shсhendrygin I N, Yakupova S P
V.A. Nasonova Research Institute of Rheumatology, Moscow, Russia.
Autonomous Healthcare Institution "Irkutsk Clinical Hospital №1", Irkutsk, Russia.
Ter Arkh. 2018 Jun 20;90(6):65-73. doi: 10.26442/terarkh201890665-73.
To identify factors affecting the effectiveness of NSAIDs in patients with OA and LBP.
An observational study was conducted to evaluate the effectiveness of a 2-week course of NSAIDs in OA and LBP in real clinical practice. The study group consisted of 3604 patients with OA and LBP (60.6% women and 39.4% men, mean age 55.0±13.4 years). According to the study design, aceclofenac (Airtal) and other NSAIDs used in the ratio 1:1. The main criterion of effectiveness was the frequency of complete pain relief after 2 weeks of therapy. In addition, the decrease of pain and general health were determined on a 10-point numerical rating scale (NRS). We compared the frequency of complete pain relief in patients who had and did not have the studied factors. The value of the studied factors was determined using OR (95% CI).
Most patients received aceclofenac (54.9%), as well as diclofenac (2.0%), ketoprofen (1.9%), lornoxicam (2.2%), meloxicam (13.7%), naproxen (2.1%), nimesulide (5.8%), celecoxib (5.9%), ethicoxib (7.1%) and other NSAIDs (4.4%); 56.2% of patients received muscle relaxants, mainly tolperisone (74.7%), vitamin B (10.4%), and proton pump inhibitors (42.8%). Complete pain relief was achieved in 54.8% of patients. The pain decrease and general health improvement were (for NRS) 63.9±13.4% and 61.7±14.8%, respectively. The efficacy of aceclofenac was slightly higher than in the whole group: complete pain relief was in 59.9% of patients. Adverse events in aceclofenac use were observed in 2.3% of patients, other NSAIDs-from 2.4 to 14.1%. The frequency of complete pain relief was higher in men: OR 1,239 (95% CI 1.08-1.418; p=0.002), who had the first episode of pain - OR 3.341 (95% CI 2.873-3.875; p=0.000), a good" response " to NSAIDs in history - OR 1.656 (95% CI 1.385-1.980; p=0.000) and received NSAIDs in combination with muscle relaxants - OR 1.218 (95% CI 1.067-1.390; p=0.004). The effect of therapy is lower in patients 65 years and older-OR 0,378 (95% CI 0.324-0.442; p=0,000), with body mass index >30 kg/m² - OR 0.619 (95% CI 0.529-0.723; p=0.000), with severe pain (≥7 points NRS) - OR 0.662 (95% CI 0.580-0.756; p=0.002), with pain at rest, - OR 0.515 (95% CI 0.450-0,589; p=0.000), pain at night - OR 0.581 (95% CI 0.501-0.672; p=0.000) and the presence of stiffness - OR 0.501 (95% CI 0.438-0,573; p=0.000). Treatment results are significantly worse in the cases of combination of LBP and joint pain, as well as pain in the trochanter major and pes anserinus area (p<0.001).
NSAIDs are the first-line medications for the pain treatment in LBP and OA. Aceclofenac is effective and safe in this conditions. When carrying out analgesic therapy should take into account factors that affect the effectiveness of treatment: old age, overweight, insufficient effect of NSAIDs in history, severe pain, signs of "inflammatory" pain, multiple sources of pain.
确定影响非甾体抗炎药(NSAIDs)对骨关节炎(OA)和腰椎间盘疼痛(LBP)患者疗效的因素。
进行一项观察性研究,以评估在实际临床实践中,为期2周的NSAIDs疗程对OA和LBP的疗效。研究组由3604例OA和LBP患者组成(女性占60.6%,男性占39.4%,平均年龄55.0±13.4岁)。根据研究设计,醋氯芬酸(艾瑞昔布)与其他NSAIDs的使用比例为1:1。疗效的主要标准是治疗2周后完全缓解疼痛的频率。此外,采用10分数字评定量表(NRS)确定疼痛减轻程度和总体健康状况。我们比较了存在和不存在所研究因素的患者中完全缓解疼痛的频率。所研究因素的值通过比值比(OR)(95%置信区间)确定。
大多数患者使用醋氯芬酸(54.9%),以及双氯芬酸(2.0%)、酮洛芬(1.9%)、氯诺昔康(2.2%)、美洛昔康(13.7%)、萘普生(2.1%)、尼美舒利(5.8%)、塞来昔布(5.9%)、依托昔布(7.1%)和其他NSAIDs(4.4%);56.2%的患者使用肌肉松弛剂,主要是甲苯哌丙酮(74.7%)、维生素B(10.4%)和质子泵抑制剂(PPI)(42.8%)。54.8%的患者实现了完全缓解疼痛。疼痛减轻程度和总体健康状况改善程度(NRS评分)分别为63.9±13.4%和61.7±14.8%。醋氯芬酸的疗效略高于整个研究组:59. % 的患者实现了完全缓解疼痛。使用醋氯芬酸的患者中2.3%发生了不良事件,其他NSAIDs为2.4%至14.1%。男性完全缓解疼痛的频率更高:比值比为1.239(95%置信区间1.08 - 1.418;p = 0.002),首次出现疼痛的患者比值比为3.341(95%置信区间2.873 - 3.875;p = 0.000),既往对NSAIDs有“良好”反应的患者比值比为1.656(95%置信区间1.385 - 1.980;p = 0.000),同时使用NSAIDs和肌肉松弛剂的患者比值比为1.218(95%置信区间1.067 - 1.390;p = 0.0)。65岁及以上患者的治疗效果较低,比值比为0.378(95%置信区间0.324 - 0.442;p = 0.000),体重指数>30kg/m²的患者比值比为0.619(95%置信区间0.529 - 0.723;p = 0.000),疼痛严重(NRS评分≥7分)的患者比值比为0.662(95%置信区间0.580 - 0.756;p = 0.002),静息痛患者比值比为0.515(95%置信区间0.450 - 0.589;p = 0.000),夜间痛患者比值比为0.581(95%置信区间0.501 - 0.672;p = 0.000),存在僵硬症状的患者比值比为0.501(95%置信区间0.438 - 0.573;p = 0.000)。在LBP合并关节痛以及大转子和鹅足区域疼痛的情况下,治疗效果明显更差(p<0.001)。
NSAIDs是LBP和OA疼痛治疗的一线药物。在这种情况下,醋氯芬酸有效且安全。进行镇痛治疗时应考虑影响治疗效果的因素:老年、超重、既往NSAIDs效果不佳、严重疼痛、“炎性”疼痛体征、多源性疼痛。